SCHEMBL16474575

SCHEMBL16474575

Cc1cc(=O)n(-c2cccc3c2OCCO3)cc1-c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 9/20 0.42
▸ DRD2 P14416 2/20 0.42
▸ DRD4 P21917 2/20 0.42
▸ HTR2B P41595 2/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ DRD3 P35462 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ P2RX7 Q99572 1/20 0.40
▸ HTR1D P28221 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ CCKAR P32238 1/20 0.38
▸ ADRB1 P08588 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474576 0.91 CYP19A1 (0.44) HTR1ADRD2DRD4HTR2BHTR2A
SCHEMBL16474618 0.83 BRD4 (0.37) HTR1ACCKAR
SCHEMBL16474572 0.81 GAA (0.48) DRD2DRD4DRD3MEN1NPC1
SCHEMBL16474619 0.78 JAK1 (0.41) HTR7MEN1KMT2ASMN1; SMN2P2RX7
SCHEMBL16474568 0.77 NOX4 (0.40) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL16475211 0.75 JAK1 (0.36) HTR7MEN1NPC1RAB9AKMT2A
SCHEMBL16474623 0.74 CYP19A1 (0.46) —
SCHEMBL16474571 0.74 CMA1 (0.46) MEN1KMT2ASMN1; SMN2
SCHEMBL16474567 0.72 ALDH1A1 (0.45) NPC1RAB9ASMN1; SMN2
SCHEMBL16475212 0.71 LMNA (0.39) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 — — EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 — — US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 — — US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 — — US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 — — US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 — — US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 — — US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 — — US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 — — US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 — — US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 — — US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 — — US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 — — US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 — — US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 — — US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 — — US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 — — WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 — — US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTR1A 2914/4885DRD2 4859/4885DRD4 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback